In the above analysis, we noted that DLG3 may affect immunotherapy efficacy in BC patients and is mainly highly expressed in malignant or suppressive cell subpopulations, so we explored the potential role of DLG3 in the immunosuppressive microenvironment of BC in a pan-cancer cohort and multiple cohorts of breast cancer. This evidence concerns the gene DLG3 and breast carcinoma.